Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Alterity Therapeutics Shares RIse 32% After Company Announced it Was Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s

By Charles Gross
Today, 4:46 PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No.11,155,547) to Alterity.

ATHE

Read More
3 minute read

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program; Clinical Trial to Enroll Patients with Early-stage Multiple Systems Atrophy

By Charles Gross
Today, 4:46 PM
Alterity Therapeutics (NASDAQ: ATHE) ("Alterity" or "the Company") today announced an expansion of the clinical development program for the Company's lead asset, ATH434, in patients with Multiple System Atrophy (MSA), a rare and rapidly progressing Parkinsonian disorder.

ATHE